With a new CEO and $12.5M in its pocket, UNC spinout sets sights on human drug trials
May 30, 2014 at 10:35 AM EDT
A drug development company that spun out of UNC-Chapel Hill brought on a CEO and now set its sights on testing its potential therapy in humans later this summer...
